Screening for sterilizing activity of antibiotic combinations in an acid model of rapidly growing mycobacteria during the stationary phase of growth

Chemotherapy

Volumn 55, Issue 2, 2009, Pages 114-118

  Cremades, R ^a   Santos, A ^a   Rodriguez J C ^a,b   Garcia Pachon E ^a   Ruiz, M ^a   Escribano, I ^a   Royo, G ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Hospital General Universitario   (Spain)

Author keywords

Bactericidal activity; Moxifloxacin; Rapidly growing mycobacteria; Stationary growing

Indexed keywords

AMIKACIN; CLARITHROMYCIN; DOXYCYCLINE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; DRUG SCREENING; GROWTH CURVE; IN VITRO STUDY; MICROORGANISM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; STERILIZATION;

EID: 58249144561     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000194973     Document Type: Article

References (33)

1. Brown-Elliott BA, Wallace RJ Jr: Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-146.
2. De Groote MA, Huitt G: Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006;42:1756-1763.
3. Petrini B: Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 2006;114:319-328.
4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007;175:367-416.
5. Rodriguez JC, Garcia-Pachón E, Ruiz M, Royo G: Drug susceptibility of the Mycobacterium genus: in vitro tests and clinical implications. Curr Clin Pharmacol 2006;1:277-289.
6. Sander P, Bottger EC: Mycobacteria: genetics of resistance and implications for treatment. Chemotherapy 1999;45:95-108.
7. Heginbothom ML: The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. Int J Tuberc Lung Dis 2001;5:539-545.
8. Marcel N, Nahta A, Balganesh M: Evaluation of killing kinetics of anti-tuberculosis drugs on Mycobacterium tuberculosis using a bacteriophage-based assay. Chemotherapy 2008;54:404-411.
9. Escribano I, Rodríguez JC, Llorca B, García-Pachon E, Ruiz M, Royo G: Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007;53:397-401.
10. Santos A, Cremades R, Rodriguez JC, Garcia-Pachón E, Ruiz M, Royo G: In vitro bactericidal activity of various drugs alone or in combination against clinical isolates of Mycobacterium fortuitum . J Infect Chemother, in press.
11. Cremades R, Santos A, Rodriguez JC, Garcia-Pachón E, Ruiz M, Royo G: In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J Chemother 2008;20:43-47.
12. Cremades R, Santos A, Rodriguez JC, Garcia-Pachón E, Ruiz M, Royo G: Multidrug resistant Mycobacterium abscessus from respiratory isolates: bactericidal activities of drug combinations. J Infect Chemother, in press.
13. Lipsitch M, Levin BR: Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998;2:187-199.
14. Garcia-Tapia A, Rodriguez JC, Ruiz M, Royo G: Action of fluoroquinolones and linezolid on logarithmic and stationary phase culture of Mycobacterium tuberculosis. Chemotherapy 2004;50:211-213.
15. Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA: Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 2006;18:617-623.
16. Ruiz M, Rodriguez JC, Escribano I, Garcia-Martinez J, Rodriguez-Valera F, Royo G: Application of molecular biology techniques to the diagnosis of nontuberculous mycobacterial infections. APMIS 2001;109:857-864.
17. Gordillo S, Guirado E, Gil O, Diaz J, Amat I, Molinos S, Vilaplana C, Ausina V, Cardona PJ: Usefulness of acr expression for monitoring latent Mycobacterium tuberculosis bacilli in 'in vitro' and 'in vivo' experimental models. Scand J Immunol 2006;64:30-39.
18. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
19. Hall-Stoodley L, Lappin-Scott H: Biofilm formation by the rapidly growing mycobacterial species Mycobacterium fortuitum. FEMS Microbiol Lett 1998;168:77-84.
20. Wallis RS, Palaci M, Eisenach K: Persistence, not resistance, is the cause of loss of isoniazid effect. J Infect Dis 2007;195:1870-1871; author reply 1872-1873.
21. Warner DF, Mizrahi V: Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 2006;19:558-570.
22. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002;6:628-634.
23. Burman WJ: The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997;313:355-363.
24. Honer zu Bentrup K, Russell DG: Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol 2001;9:597-605.
25. Dick T: Dormant tubercle bacilli: the key to more effective TB chemotherapy? J Antimicrob Chemother 2001;47:117-118.
26. Drlica K, Xu C, Wang JY, Burger RM, Malik M: Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob Agents Chemother 1996;40:1594-1599.
27. Gillespie SH, Morrissey I, Everett D: A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 2001;50:565-570.
28. Guillemin I, Jarlier V, Cambau E: Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998;42:2084-2088.
29. Dong Y, Xu C, Zhao X, Domagala J, Drlica K: Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998;42:2978-2984.
30. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2003;24.
31. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G: In vitro activity of new fluoroquinolones and linezolid against non-tuberculous Mycobacteria. Int J Antimicrob Agents 2003;21:585-588.
32. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Royo G: Mutant prevention concentration: a new tool for choosing treatment in nontuberculous mycobacterial infections. Int J Antimicrob Agents 2004;24:352-356.
33. Allerberger F, Lechner A, Wechsler-Fördös A, Gareis R: Optimization of antibiotic use in hospitals - antimicrobial stewardship and the EU project ABS international. Chemotherapy 2008;54:260-267.